Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Kybella expert, Beverly Hills Plastic Surgeon, Dr. Glenn Vallecillos, Weighs in On Kybella- An FDA-Approved Injectable Treatment For Fat Beneath the Chin
  • USA - English


News provided by

Glenn Vallecillos, MD, FACS

Feb 20, 2016, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Kybella patient before and after treatment
Kybella patient before and after treatment

Beverly Hills, California (PRWEB) February 20, 2016 -- Dr. Glenn Vallecillos, Beverly Hills plastic surgeon and nationally recognized leader in minimally invasive cosmetic treatments, speaks out in support of Kybella to treat the appearance of moderate to severe fat beneath the chin. Kybella is the first and only FDA-approved injectable treatment that works to destroy fat cells under the chin.

In over 20 clinical trials, more than 1,600 patients received treatment with Kybella. These patients reported improvement in both their appearance and emotional outlook regarding their new profile.

Post this

"The active ingredient in Kybella occurs naturally in the body," says Dr. Vallecillos. "This acid helps the body break down and absorb fats. Injecting Kybella into the treatment area destroys those fat cells. More than half of my facial plastic surgery patients complain about fat beneath the chin, which we call submental fullness. Kybella's FDA approval and extensive clinical trials, combined with the non-invasive nature of the technique, make it a procedure I fully support."

In over 20 clinical trials, more than 1,600 patients received treatment with Kybella. These patients reported improvement in both their appearance and emotional outlook regarding their new profile. Dr. Vallecillos advises, "Patients who are basically healthy but suffer from submental fullness despite regular exercise and a balanced diet may be good candidates for Kybella treatments."

Kybella is a viable option for patients complaining of submental fullness who do not want to undergo an invasive surgical procedure. No matter what caused the patient's condition, whether age, weight gain, or heredity, Kybella offers a solution with minimal side effects and lasting results.

When injected beneath the chin, Kybella destroys fat cells, making it impossible for them to store fat. The patient's body processes the fat through its natural metabolism. Patients may require up to six separate treatments, but once complete, no further treatments are necessary.

Side effects are typically mild, according to Dr. Vallecillos, and may include:

• Swelling
• Bruising
• Pain
• Numbness
• Redness
• Areas of hardness in the treatment area

Dr. Vallecillos advises patients that side effects that are more serious are possible, so they should share their full medical history with their physician, including prior facial surgeries, current prescriptions and supplements, as well as whether they are pregnant or nursing.

As a recognized expert in nonsurgical rejuvenation, Dr. Vallecillos speaks locally, nationally, and internationally about his passion for minimally invasive cosmetic treatments. He has also trained hundreds of top physicians and surgeons on non-invasive aesthetic procedures, including advanced injection techniques.

A practicing plastic surgeon since 2005, Dr. Vallecillos' goal regarding cosmetic enhancement is to create a natural appearance that complements the patient's features. He bases his practice on evidence-based medicine. Patient consultations include extensive education to help create realistic expectations of procedure results, along with gathering pertinent patient information, such as his or her aesthetic goals and medical history.

Located in the heart of the Beverly Hills Medical District, Dr. Vallecillos' facility offers patients state-of-the-art equipment and JHACO-accredited operative theaters. His staff is knowledgeable and supportive, and he offers patients an array of comfortable accommodations, including a VIP waiting area with complimentary beverages and snacks.

In addition to a thriving medical practice and active public speaking schedule, Dr. Vallecillos is a regular contributor to The European Journal of Plastic Surgery and InStyle's Best Beauty Buys, and he is a contributing editor to Sherdog and SheKnows. Additionally, he has appeared on CNN's Larry King Live, Inside Edition, and Fox News.

Drue Maggetti, Glenn Vallecillos, MD, FACS, +1 (310) 273-3007 Ext: 1, [email protected]

Modal title

Glenn Vallecillos, MD, FACS
Glenn Vallecillos, MD, FACS
Submental fullness improvements after 1, 2, and 3 Kybella treatments
Submental fullness improvements after 1, 2, and 3 Kybella treatments
Kybella Treatment Male Before & Afters
Kybella Treatment Male Before & Afters
Glenn Vallecillos, MD, FACS Submental fullness improvements after 1, 2, and 3 Kybella treatments Kybella Treatment Male Before & Afters

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.